PhillyInc

Ed Silverman at Pharmalot spotted this from OutSourcing-Pharma.com: The sell-side investment advisory firm Dresdner Kleinwort is predicting in a new analyst report that AstraZeneca PLC, now under the tutelage of ex-Wilmington-based U.S. division chief David Brennan, will wither in the coming eight years if something drastic isn't done. They say their worst-case disaster scenario "has a 50% probability of occurring." Brennan left Wilmington for London a couple a years ago, taking some top people with him. Certainly the reign of ex-CEO and founder Tom McKillop needed a shakeup. But Brennan has struggled since his ascent, reinvigorating the old talk of a merger or buyout with GlaxoSmithKline PLC.

- Thomas Ginsberg